Business Context and Reporting Period
Company: Lexaria Bioscience Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: May 4, 2020
Event: Entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $2,064,998.
- Securities Issued: 8,978,254 shares of common stock and warrants to purchase an equal number of shares.
- Warrant Terms: Exercise price of $0.35 per share; 5-year term (expiring May 6, 2025); cashless exercise option available if shares are not registered.
- Placement Agent Fees: Cash fee of approximately $154,200 plus 8% of proceeds from cash warrant exercises; reimbursement of legal fees up to $25,000; issuance of 658,087 warrants to the agent.
- Use of Proceeds: Funding a human pilot study for DehydraTECH technology (antiviral bioavailability), senior US exchange listing application, and general working capital.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement with certain investors. The first tranche closed on May 6, 2020, involving 8,028,254 shares and warrants, with the remaining 950,000 shares and warrants anticipated to be issued shortly thereafter.
- Registration Rights: The Company must file a resale registration statement within 30 days of closing and have it declared effective within 60 to 120 days, depending on SEC review. Liquidated damages apply for failure to meet these deadlines.
- Future Financing Restrictions: Investors investing at least $115,000 have a right to participate in up to 50% of subsequent financings for 18 months. The Company cannot effect a subsequent financing within 90 days of the Resale Date without consent from investors holding 50.1% of the initial subscription.
- Lock-Up Agreements: Officers and directors are locked up for 90 days after the Resale Date. Investors are locked up until the later of the Effective Date or September 6, 2020.
Guidance, Outlook, and Risks
Outlook: Management intends to utilize proceeds to advance clinical research on DehydraTECH technology for potential use against COVID-19 and to pursue a listing on a senior US exchange.
Risks and Contingencies:
- Registration Risk: Failure to timely file or maintain the effectiveness of the resale registration statement triggers liquidated damages.
- Dilution: Warrants are subject to anti-dilution adjustments for stock splits and dividends.
- Financing Constraints: The Company's ability to raise future capital is restricted by the 90-day blackout period and investor consent requirements.
Investor Verification Checklist
- Verify the closing status of the remaining 950,000 shares and warrants.
- Confirm the filing date and effectiveness status of the resale registration statement (Exhibit 10.3).
- Review the specific terms of the DehydraTECH pilot study to assess the likelihood of successful clinical outcomes.
- Monitor the Company's progress toward a senior US exchange listing application.
- Check for any subsequent financings that may trigger investor participation rights or require consent.